Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis.

JNCI Cancer Spectr · 2019 · PMC6649709 · PMID 31360906

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Studies using trastuzumab for 9–12 weeks showed worse DFS than trastuzumab treatment for 6 months (HR = 1.28, 95% CI = 1.09 to 1.50 vs HR = 1.09, 95% CI = 0.98 to 1.20), but this did not reach statistical significance ( P subgroup difference = .09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.